澳大利亚生物技术公司Mesoblast Limited（ASX: MSB）今日盘中股价大涨6.72%，引起投资者广泛关注。
此轮涨势主要源于公司发布的积极财务预期。Mesoblast预计截至2025年12月31日的季度毛收入将超过3000万美元，这一收入主要来自其重磅产品Ryoncil的销售。这一预期显著超出了市场此前的预估，体现了公司业务的强劲增长。
Ryoncil是Mesoblast的主打产品，用于治疗急性移植物抗宿主病（aGVHD）。该产品的强劲销售表现不仅直接提升了公司的财务状况，也增强了投资者对Mesoblast长期发展前景的信心。这一收入预期的公布，凸显了公司在生物制药领域的竞争优势，并可能预示着未来更广阔的市场机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.